Floatz logo

Idarubicin

Lymphoblastic Lymphoma

St. Jude Children's Research HospitalSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
89/ 100

Competitive context

73 Active assets in the Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
Rituximab
University of Washington
Phase 4BBB
Cladribine
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 4BBB
MERCAPTOPURINE ANHYDROUS
City of Hope Medical Center
Phase 4BBB
PEGASPARGASE
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 4BBB
VINDESINE
University Hospital Muenster
Phase 4BBB

View all 50 →

Same molecule, other indications

Idarubicin is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative · Phase 4
81 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
BBB
Indicative · Phase 2
76 / 100
View asset →
adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →